매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +15.6% 성장하면서 영업이익률이 -2.8%에서 4.3%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +15.6%영업이익률 -2.8%→4.3%FCF 6,935
Kukje Pharma
002720 · KOSPI₩3,415+0.89%
2026-09-04 closeKukje Pharma last closed at ₩3,415 (+0.89%) on 2026-09-04. Listed on KOSPI; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
B
Overall: 건강관리 128/291 · top 44%
Factor composite · relative position in sector
PER 13.88 · PBR 0.81 — own-history percentile 100/100 · 77/100
Open self-history band
PER100/100
PBR77/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 1 consecutive years · Raised 0 consecutive years · Yield 0.88% (based on 2025 payment of 30원)
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.74
Distress
Grey
Safe
- Altman Z''
- 2.74
- Beneish M-Score
- -2.32
- Sloan accrual
- 0.76%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
8/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score8/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityWarning
OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 46% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 81 of 287, share 0.3%.
81 / 2870.3%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6국제약품0.3%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 4.3%
- Interest coverage
- 5.5x
- Return on equity (ROE)
- 5.8%
Operating margin −5pp
Operating lossInterest coverageBase 5.5x adverse case -1x
Return on equity (ROE)Base 5.8% adverse case -2.6%
Revenue −15%
TolerableInterest coverageBase 5.5x adverse case 4.7x
Return on equity (ROE)Base 5.8% adverse case 5%
Interest rate +2pp
TolerableInterest coverageBase 5.5x adverse case 2.4x
Return on equity (ROE)Base 5.8% adverse case 4.4%
Interest coverage limit
Current margin 3.5ppInterest coverage limit at an operating margin of 0.8%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
삼오제약강일케미팜삼오파마켐ACRAFSPA
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 남영우37.95%2026-08-11 · 증감 +0.02%p
Connections
AI-extracted related companies · for reference
Competitors
삼성바이오로직스Price comovement r=0.22 (1 year)셀트리온Price comovement r=0.38 (1 year)유한양행Price comovement r=0.44 (1 year)녹십자Price comovement r=0.50 (1 year)대웅제약Price comovement r=0.37 (1 year)종근당Price comovement r=0.36 (1 year)동아에스티Price comovement r=0.55 (1 year)한미약품Price comovement r=0.39 (1 year)일동제약Price comovement r=0.28 (1 year)JW중외제약Price comovement r=0.55 (1 year)신신제약Price comovement r=0.41 (1 year)동화약품Price comovement r=0.61 (1 year)삼일제약Price comovement r=0.45 (1 year)
Same theme
Recent filings
Kukje Pharma's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Kukje Pharma
- What technical signals does Kukje Pharma (002720) have?
- Kukje Pharma current technical signals: no active technical signal.
- Is Kukje Pharma a cup-and-handle pattern?
- No. Kukje Pharma has no valid cup-and-handle signal right now.
- What are Kukje Pharma's financials and valuation?
- Kukje Pharma's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy